Efficacy of voxel-based dosimetry map for predicting response to trans-arterial radioembolization therapy for hepatocellular carcinoma: a pilot study
暂无分享,去创建一个
J. S. Lee | Min Young Yoo | G. Cheon | D. Lee | K. Kang | J. Paeng | M. S. Lee | Hyo-Choel Kim | J. Lee
[1] S. Kappadath,et al. Planning Dosimetry for 90 Y Radioembolization with Glass Microspheres: Evaluating the Fidelity of 99m Tc-MAA and Partition Model Predictions. , 2020, Medical physics.
[2] R. Braren,et al. Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study , 2019, European journal of gastroenterology & hepatology.
[3] E. Assenat,et al. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. , 2018, Journal of vascular and interventional radiology : JVIR.
[4] B. Kunnen,et al. The physics of radioembolization , 2018, EJNMMI Physics.
[5] N. Molinari,et al. Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome , 2018, The Journal of Nuclear Medicine.
[6] P. Flamen,et al. 90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer , 2018, EJNMMI Research.
[7] G. Cheon,et al. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on 99mTc-MAA Imaging and Correlation With Treatment Efficacy , 2015, Medicine.
[8] P. Flamen,et al. Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres , 2014, The Journal of Nuclear Medicine.
[9] F. Orsi,et al. Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective , 2014, Front. Oncol..
[10] A. Pasciak,et al. A Comparison of Techniques for 90Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres , 2014, Front. Oncol..
[11] Marnix G E H Lam,et al. 99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.
[12] T. Therneau,et al. Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma , 2013, CardioVascular and Interventional Radiology.
[13] K. Boudjema,et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Hiroki Kato,et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT , 2012, Annals of Nuclear Medicine.
[15] Bruno Sangro,et al. Radioembolization for hepatocellular carcinoma. , 2012, Journal of hepatology.
[16] N. Lanconelli,et al. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions , 2012, Physics in medicine and biology.
[17] Tim Meyer,et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.
[18] Wenzheng Feng,et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90 Y microsphere brachytherapy in the treatment of hepatic malignancies. , 2011, Medical physics.
[19] I. Gardin,et al. Fine-Resolution Voxel S Values for Constructing Absorbed Dose Distributions at Variable Voxel Size , 2010, The Journal of Nuclear Medicine.
[20] L. Schwartz,et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Sotiropoulos,et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[23] M. Abecassis,et al. A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[25] S. Gulec,et al. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[27] A. Li,et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours , 1996, European Journal of Nuclear Medicine.
[28] P. Wallner,et al. Quantitative bremsstrahlung single photon emission computed tomographic imaging: use for volume, activity, and absorbed dose calculations. , 1995, International journal of radiation oncology, biology, physics.
[29] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[30] U. Settmacher,et al. [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. , 2016, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[31] Wenzheng Feng,et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. , 2011, Medical physics.
[32] W E Bolch,et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] J. Siegel,et al. Therapeutic beta irradiating isotopes in bony metastasis : a technique for bremsstrahlung imaging and quantitation , 1992 .